Core Viewpoint - Weigao Co., Ltd. is experiencing a decline in stock price following the announcement of a significant acquisition aimed at enhancing its business portfolio and profitability [1] Group 1: Acquisition Details - Weigao Co., Ltd. plans to acquire 100% equity of Weigao Purui from three parties for approximately 8.511 billion yuan [1] - Upon completion of the transaction, Weigao Purui will become a wholly-owned subsidiary, adding pharmaceutical packaging business to the company's main operations [1] Group 2: Market Position and Impact - Weigao Purui holds the largest market share in pre-filled products in China, exceeding 50% from 2022 to 2024, and ranks first in the domestic market [1] - The company is also among the top five in international sales within the industry [1] - The acquisition is expected to enhance the company's profitability and investment value by incorporating a high-quality asset into its consolidated financial statements [1]

消息面上，1月5日，威高血净（603014）发布公告，拟通过发行股份的方式购买威高股份、威海盛熙和 威海瑞明3名交易对方持有的威高普瑞100%股权，交易价格约为85.11亿元。交易完成后威高普瑞将成 为公司全资子公司，公司主营业务将新增医药包材相关业务。 公告显示，威高普瑞预灌封产品市占率居国内第一。根据中国医药包装协会出具的说明，2022年至2024 年，威高普瑞预灌封产品国内市场占比均超过50%，在国内市场行业中排名第一，在国际市场销量位列 行业前五。威高血净称，本次交易完成后，威高普瑞作为盈利能力较强的优质资产将纳入上市公司合并 报表范围，将进一步提高上市公司盈利能力和投资价值。 威高股份(01066)早盘跌超5%，截至发稿，跌4.91%，报5.04港元，成交额1846.65万港元。 ...